Pharmacological treatment of sleep disturbance in developmental disabilities: A review of the literature

Research in Developmental Disabilities

Volumn 32, Issue 3, 2011, Pages 939-962

  Hollway, Jill A ^a   Aman, Michael G ^a  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

Author keywords

Children; Developmental disabilities; Pharmocology; Sleep disturbance

Indexed keywords

ALIMEMAZINE TARTRATE; AMITRIPTYLINE; ANTIHISTAMINIC AGENT; BENZODIAZEPINE DERIVATIVE; CLONAZEPAM; CLONIDINE; DEXTROMETHORPHAN; DIPHENHYDRAMINE; ESZOPICLONE; FLUOXETINE; FLURAZEPAM; HALOPERIDOL; IMIPRAMINE; MELATONIN; MIRTAZAPINE; NIAPRAZINE; OLANZAPINE; PAROXETINE; PLACEBO; PROMETHAZINE; RAMELTEON; RISPERIDONE; ROZAREM; TRAZODONE; TRIAZOLAM; UNCLASSIFIED DRUG; YOHIMBINE; ZALEPLON; ZOLPIDEM; ZOLPIDEM TARTRATE;

ABSENCE OF SIDE EFFECTS; ANTICHOLINERGIC SYNDROME; ANXIETY; ATTENTION DEFICIT DISORDER; BEDTIME DOSAGE; BEHAVIOR MODIFICATION; BRUXISM; COGNITIVE THERAPY; DEPRESSION; DEVELOPMENTAL DISORDER; DOSE RESPONSE; DROWSINESS; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EVENING DOSAGE; HALLUCINATION; HUMAN; INCREASED APPETITE; INSOMNIA; IRRITABILITY; MAJOR DEPRESSION; NAUSEA; NAUSEA AND VOMITING; OPTIMAL DRUG DOSE; PARASOMNIA; POLYSOMNOGRAPHY; REINFORCEMENT; REVIEW; SEDATION; SIDE EFFECT; SLEEP AROUSAL DISORDER; SLEEP DISORDER; SYSTEMATIC REVIEW; TIME TO MAXIMUM PLASMA CONCENTRATION; TRANSIENT ISCHEMIC ATTACK; UNSPECIFIED SIDE EFFECT;

ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; CENTRAL NERVOUS SYSTEM DEPRESSANTS; DEVELOPMENTAL DISABILITIES; HUMANS; HYPNOTICS AND SEDATIVES; MELATONIN; SLEEP DISORDERS;

EID: 79952446501     PISSN: 08914222     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ridd.2010.12.035     Document Type: Review

References (121)

1. Akhondzadeh S., Tajdar H., Mohammadi M.R., Mohammadi M., Nouroozineja G.H., Shabstari O.L., et al. A double-blind placebo controlled trial of piracetam added to risperidone in patients with autistic disorder. Child Psychiatry and Human Development 2008, 39:237-245.
2. Aman M.G., Arnold L.E., McDougle C.J., Vitiello B., Scahill L., Davies M., et al. Acute and long-term safety and tolerability of risperidone in children with autism. Journal of Child and Adolescent Psychopharmacology 2005, 15:869-884.
3. Aman M.G., Lam K.S.L., Collier-Crespin A. Prevalence and patterns of use of psychoactive medicines among individuals with autism in the Autism Society of Ohio. Journal of Autism and Developmental Disorders 2003, 33:527-534.
4. American Academy of Sleep Medicine. (2001). International classification of sleep disorders, revised: Diagnostic and coding manual. Chicago, Illinois.
5. Arana-Lechuga Y., Sanchez-Escandón O., Castillo-Montya C., Terán-Pérez G., Velázquez-Moctezuma J. Risperidone treatment of sleep disturbances in Tourette's Syndrome. Journal of Neuropsychiatry and Clinical Neuroscience 2008, 20:375-376.
6. Arens R., Wright B., Elliot J., Zhao H., Wang P.P., Brown L.W. Periodic limb movement in children with Williams Syndrome. Journal of Pediatrics 1998, 133:670-674.
7. Armour A., Gottschlich M.M., Khoury J., Warden G.D., Kagan R.J. A randomized, controlled prospective trial of zolpidem and haloperidol for use as sleeping agents in pediatric burn patients. Journal of Burn Care Research 2008, 29:238-247.
8. Aton S.J, Seibt J., Dumoulin M., Jha S.K., Steinmetz N., Coleman T., et al. Mechanisms of sleep-dependent consolidation of cortical plasticity. Neuron 2009, 61:455-466.
9. Balon R. Sleep terror disorder and insomnia treated with trazodone: A case report. Annals of Clinical Psychiatry 1994, 6:161-163.
10. Barbera J., Shapiro C. Benefit-risk assessment of zaleplon in the treatment of insomnia. Drug Safety 2005, 28:301-318.
11. Bezchlibnyk-Butler K., Jeffries J.J. Clinical handbook of psychotropic drugs 2005, Hogrefe & Huber Publishers, Ashland, OH. 16th ed.
12. Biederman J., Mick E., Farone S.V., Wozniak J., Spencer T., Pandina G. Risperidone for the treatment of affective symptoms in children with disruptive behavior disorder: A post hoc analysis of data from a 6-week, multicenter, randomized, double-blind, parallel-arm study. Clinical Therapeutics 2006, 28:794-800.
13. Blumer, J. L., Findling, R. L., Shih, W. J., Soubrane, C., & Reed, M. D. (2009). Controlled trial of zolpidem for the treatment of insomnia associated with attention-deficit/hyperactivity disorder in children 6 to 17 years of age. Pediatrics, 123, e770-6 [Retrieved May 14, 2009, from at Nationwide Children's Hospital]. http://www.pediatrics.org/.
14. Blumer J.L., Reed M.D., Steinberg F., O'Riordon M.A., Rosen C.L., Springer M.A., et al. Potential pharmacokinetic basis for zolidem dosing in children with sleep difficulties. Clinical Pharmacology 2008, 83:551-558.
15. Braam W., Didden R., Smits M.G., Curfs L.M.G. Melatonin treatment in individuals with intellectual disability and chronic insomnia: A randomized placebo-controlled study. Journal of Intellectual Disability Research 2008, 52:256-264.
16. Braam W., Didden R., Smits M.G., Leopold M.G., Curfs L.M.G. Melatonin for chronic insomnia in Angelman's Syndrome: A randomized placebo-controlled trial. Journal of Child Neurology 2008, 23:649-654.
17. Carskadon M.A., Seifer R., Acebo C. Reliability of six scales in a sleep questionnaire for adolescents. Sleep Research 1991, 20:421.
18. Camfield P., Gordon K., Dooley C., Camfield C. Melatonin appears ineffective in children with intellectual deficits and fragmented sleep: Six " N of 1" trials. Journal of Child Neurology 1996, 11:341-343.
19. Colle M., Rosensweig P., Bianchetti G., Fuseau E., Ruffie A., Ruedas E., et al. Nocturnal profile of growth hormone secretion during sleep induced by zolpidem: A double-blind study in young adults and children. Hormone Research 1991, 35:30-34.
20. Coppola G., Iervolino G., Mastrosimone M., La Torre G., Ruiu F., Pascotto A. Melatonin in wake-sleep disorders in children, adolescents and young adults with mental retardation wit or without epilepsy: A double-blind, crossover, placebo-controlled trial. Brain and Development 2004, 26:373-376.
21. Cooper, Heron, Heward Applied behavior analysis 1987, Prentice Hall, New Jersey.
22. Didden R., Sigafoos J. A review of the nature and treatment of sleep disorders in individuals with developmental disabilities. Research in Developmental Disabilities 2001, 22:255-272.
23. Drake C.L., Roehrs T.A., Mangano R.M., Roth T. Dose-response effects of zaleplon as compared with triazolam (0.25) and PBO in chronic primary insomnia. Human Psychopharmocology: Clinical and Experimental 2000, 15:595-604.
24. Drover Comparative pharmacokinetics and pharmacodynamics of short-acting hypnosedatives: Zaleplon, zolpidem and zopiclone. Clinical Pharmacokinetics 2004, 43:227-238.
25. Edinger J.D., Fins A.I., Sullivan R.J., Marsh G.R., Dailey D.S., Young M. Comparison of cognitive-behavioral therapy and clonazepam for treating periodic limb movement disorder. Sleep 1996, 19:442-444.
26. Efron D., Hiscock H., Sewell J.R., Cranswick N.E., Vance A.L.A., Tyl Y., et al. Prescribing of psychotropic medications for children by Australian pediatricians and child psychiatrists. Pediatrics 2003, 111:372-375.
27. Elie R., Rüther E., Farr I., Emilien G., Salinas E., for the Zaleplon Clinical Study Group Sleep latency is shortened during 4 weeks of treatment with zaleplon, a novel nonbenzodiazepine hypnotic. Journal of Clinical Psychiatry 1999, 60:536-544.
28. Erman M, Seiden D., Zammit G., Sainati S., Zhang J. An efficacy, safety, and dose-response study of ramelteon in patients with chronic primary insomnia. Sleep Medicine 2006, 7:17-24.
29. Espie C.A., Paul A., McFie J., Amos A., Hamilton D., McColl J.H., et al. Sleep studies of adults with severe or profound mental retardation and epilepsy. American Journal of Mental Retardation 1998, 103:47-59.
30. Espie C.A., Tweedie F.M. Sleep patterns and sleep problems amongst people with mental handicap. Journal of Mental Deficiency 1991, 35:25-36.
31. France K.G., Blampied N.M., Wilkinson P. Treatment of infant sleep disturbance by trimeprazine in combination with extinction. Journal of Developmental & Behavioral Pediatrics 1991, 12:308-314.
32. Gaillard J.M., Blois R. Differential effects of flunitrazepam on human sleep in combination with flumazenil. Sleep 1989, 12:120-132.
33. Gais S., Plihal W., Wagner U., Born J. Early sleep triggers memory for early visual discrimination skills. Nature Neuroscience 2000, 3:1335-1339.
34. Garstang J., Wallis M. Randomized controlled trial of Melatonin for children with autistic spectrum disorders and sleep problems. Child: Care, Health and Development 2006, 32:585-589.
35. Gentili A., Godschalk M.F., Gheorghiu D., Nelson K., Julius D.A., Mulligan T. Effect of clonidine and yohimbine on sleep in healthy men: A double-blind, randomized, controlled trial. European Journal of Pharmacodynamics 1996, 50:463-465.
36. Goraya J.S., Virdi V., Parmar V. Recurrent nocturnal tongue biting in a child with hereditary chin trembling. Journal of Child Neurology 2006, 21:985-987.
37. Harvey M.T., Kennedy C.H. Polysomnographic phenotypes in developmental disabilities. International Journal of Developmental Neuroscience 2002, 20:443-448.
38. Hancock E., O'Callaghan F., Osborne J.P. Effect of Melatonin dosage on sleep disorder in Tuberous Sclerosis Complex. Journal of Child Neurobiology 2005, 20:78-80.
39. Hedner J., Yaeche R., Emilien G., Farr I., Salinas E., The Zaleplon Clinical Study Group Zaleplon shortens subjective sleep latency and improves subjective sleep quality in elderly patients with insomnia. International Journal of Geriatric Psychiatry 2000, 15:704-712.
40. Hoffman K.L., McNaughton B.L. Sleep on it: Cortical reorganization after-the-fact. Trends in Neuroscience 2002, 25:1-2.
41. Holbrook A.M., Crowther R., Lotter A., Cheng C., King D. Meta-analysis of benzodiazepine use in the treatment of insomnia. Canadian Medical Association Journal 2000, 162:225-233.
42. Ingrassia A., Turk J. The use of clonidine for severe and intractable sleep problems in children with neurodevelopmental disorders: A case series. European Child & Adolescent Psychiatry 2005, 14:34-40.
43. Johnson K.P., Malow B.A. Assessment and pharmacologic treatment of sleep disturbance in autism. Child and Adolescent Psychiatric Clinics of North America 2008, 17:773-785.
44. Kallepalli B.R., Bhatara V.S., Fogas B.S., Tervo R.C., Misra L.K. Trazodone is only slightly faster than fluoxetine in relieving insomnia in adolescent with depressive disorders. Journal of Child an Adolescent Psychopharmacology 1997, 7:97-107.
45. Karim A., Tolbert D., Cao C. Disposition kinetics and tolerance of escalating single doses of ramelteon, a high-affinity MT1 and MT2 melatonin receptor agonist indicated for treatment of insomnia. Journal of Clinical Pharmacology 2006, 46:140-148.
46. Kryger R.H., Steljes D., Pouliot Z., Neufeld H., Odynski T. Subjective versus objective evaluation of hypnotic efficacy. Experience with zolpidem. Sleep 1991, 14:399-407.
47. Kupfer D.J., Coble P., Kane J., Petti T., Conners C.K. Imipramine and EEG sleep in children with depressive symptoms. Psychopharmacology 1979, 60:117-123.
48. Kupfer D.J., Reynolds C.F. Management of insomnia. New England Journal of Medicine 1997, 336:341-345.
49. Kupfer D.J., Spiker D.G., Coble P., McPartland R.J. Amitriptyline and EEG sleep in depressed patients: I. Drug effect. Sleep 1978, 1:149-159.
50. Lancel L. Role of GABAA receptors in the regulation of sleep: Initial sleep responses to peripherally administered modulators and agonists. Sleep 1999, 22:33-42.
51. Langworthy-Lam K.S., Aman M.G., Van Bourgondien M.E. Prevalence and patterns of use of psychoactive medicines in individuals with autism in the Autism Society of North Carolina. Journal of Child and Adolescent Psychopharmacology 2002, 12:311-321.
52. Laureys S., Peigneux P., Phillips C., Fuch S., Degueldre C., Aerts J., et al. Experience-dependent changes in cerebral functional connectivity during human rapid eye movement sleep. Neuroscience 2001, 105:521-525.
53. Leblanc J.C., Bidner C.E., Armenteros J.L., Aman M.G., Wang J.S., Hew H., et al. Risperidone reduces aggression in boys with a disruptive behavior disorder and below average intelligence quotient: Analysis of two placebo-controlled randomized trials. International Clinical Psychopharmacology 2005, 20:275-283.
54. Lewis S.A. Sleep patterns during afternoon naps in the young and elderly. British Journal of Psychiatry 1969, 115:107-108.
55. Luthringer R., Muzet M., Zisapel N., Staner L. The effect of prolonged-release melatonin on sleep measures and psychomotor performance in elderly patients with insomnia. International Clinical Psychopharmacology 2009, 24:239-249.
56. Maquet P., Laureys S., Peigneux P., Fuchs S., Petiau C., Phillips C., et al. Experience-dependent changes in cerebral activation during human REM sleep. Nature Neuroscience 2000, 3:831-836.
57. McArthur A.J., Budden S.S. Sleep dysfunction in Rett Syndrome: A trial of exogenous melatonin treatment. Developmental Medicine & Child Neurology 1998, 40:186-192.
58. Meltzer L.J., Mindell J.A., Owens J.A., Byars K.C. Use of sleep medications in hospitalized pediatric patients. Pediatrics 2007, 119:1047-1055.
59. Mendelson W.B. A review of the evidence for the efficacy and safety of trazodone in insomnia. Journal of Clinical Psychiatry 2005, 66:469-476.
60. Merentstein D., Diener-West M., Halbower A.C., Krist A., Rubin H.R. The trial of infant response to diphenhydramine: The TIRED study. Archives of Pediatric & Adolescent Medicine 2006, 160:707-712.
61. Mindel J.A., Emslie G., Blumer J., Genel M., Glaze D., Ivanenko A., et al. Pharmacological management of insomnia in children and adolescents: Consensus statement. Pediatrics 2006, 117:e1223-e1232.
62. Ming X., Gordon E., Kang N., Wagner G.C. Use of clonidine with autism spectrum disorders. Brain & Development 2008, 30:454-460.
63. Moser D., Anderer P., Gruber G., Parapatics S., Loretz E., Boeck M.K., et al. Sleep classification according the AASM and Rechtschaffen & Kales: Effects on sleep scoring parameters. Sleep 2009, 32:139-149.
64. Niederhofer H., Staffen W., Mair A., Pittschieler K. Brief report: Melatonin facilitates sleep in individuals with mental retardation and insomnia. Journal of Autism and Developmental Disorders 2003, 33:469-472.
65. O'Callaghan F.J.K., Clarke A.A., Hancock E., Hunt A., Osborne J.P. Use of Melatonin to treat sleep disorders in tuberous sclerosis. Developmental Medicine & Child Neurology 1999, 41:123-126.
66. Ottaviano S., Giannotti F., Cortesi F. The effect of niaprazine on some common sleep disorders in children: A double-blind clinical trial by means of continuous home-video recorded sleep. Child's Nervous System 1991, 7:332-335.
67. Owens J.A. Pharmacotherapy of Pediatric Insomnia. Journal of the American Academy of Child and Adolescent Psychiatry 2009, 48:99-107.
68. Owens J.A., Babcock D., Blumer J., Chervin R., Ferber R., Goetting M., et al. The use of pharmacotherapy in the treatment of pediatric insomnia in primary care: Rational approaches. A consensus meeting summary. Journal of Clinical Sleep Medicine 2005, 1:49-58.
69. Owens J.A., Palermo T.M., Rosen C.L. Overview of current management of sleep disturbances in children: II-Behavioral interventions. Current Therapeutic Research 2002, 63(Suppl. B):B38-B52.
70. Owens J.A., Rosen C.L., Mindell J.A. Medication use in the treatment of pediatric insomnia: Results of a survey of community-based pediatricians. Pediatrics 2003, 111:e628-e635.
71. Palermo T.M., Koren G., Blumer J.L. Rational pharmacotherapy for childhood sleep disturbances: Characterstics of an ideal hypnotic. Current Therapeutic Research 2002, B63:B67-B79.
72. Paul I.M., Yoder K.E., Crowell K.R., Shaffer M.L., McMillan H.S., Carlson L.C., et al. Effect of dextromethorphan, diphenhydramine, and placebo on nocturnal cough and sleep quality for coughing children and their parents. Pediatrics 2004, 114:e85-e90.
73. Peled R., Lavie P. Double-blind evaluation of clonazepam on periodic leg movements in sleep. Journal of Neurology, Neurosurgery, and Psychiatry 1987, 50:1679-1681.
74. Pelayo R., Chen W., Monzon S., Guilleminault C. Pediatric sleep pharmacology: You want to give my kid sleeping pills?. Pediatric Clinics of North America 2004, 51:117-134.
75. Pelayo R., Dubik M. Pediatric sleep pharmacology. Seminars in Pediatric Neurology 2008, 15:79-90.
76. Posey D.J., Guenn K.D., Kohn A., Swiezy N.B., McDougle C.J. A naturalistic open-label study of mirtazapine in autistic and other pervasive developmental disorders. Journal of Child and Adolescent Psychopharmacology 2001, 11:267-277.
77. Pranzatelli M.R., Tate E.D., Dukart W.S., Flint M.J., Hoffman M.T., Oksa A.E. Sleep disturbance and rage attacks in opsoclonus-myoclonus syndrome: Response to trazodone. Journal of Pediatrics 2005, 147:372-378.
78. Prince J.B., Wilens T.E., Biederman J., Spencer T.J., Wosniak J.R. Clonidine for sleep disturbances associated with attentions deficit hyperactivity disorder: A systematic chart review of 62 cases. Journal of the American Academy of Child and Adolescent Psychiatry 1996, 35:599-605.
79. A manual of standardized terminology, techniques and scoring system for sleep stages of human subjects. 1968, U.S. Government Printing Office, NIH publication No. 204, Washington, DC. A. Rechtchaffen, A. Kales (Eds.).
80. Reimão R., Lefėvre A.B. Evaluation of flurazepam and placebo on sleep disorders in childhood. Arquivos de Neuro-Psiquiatria (São Paulo) 1982, 40:1-13.
81. Research Units on Pediatric Psychopharmacology (RUPP) Autism Network, McCracken, J.T., McGough, J., Shah, B., Cronin, P., Hong, D., Aman, M.G., Arnold, L.E., Lindsay, R., Nash, P., Hollway, J.A., McDougle, C.J., Posey, D., Swiezy, N., Kohn, A., Scahill, L., Martin, A., Koenig, K., Volkmar, F., Carroll, D., Lancor, A., Tierney, E., Ghuman, J., Gonzalez, N.M., Grados, M., Vitiello, B., Ritz, L., Davies, M., Robinson, J., McMahon, D. (2002). Randomized clinical trial of risperidone for irritability in autism. New England Journal of Medicine, 347, 314-321.
82. Reyes M., Buitelaar J., Toren P., Augustyns I., Eerdekens M. A randomized, double-blind, placebo-controlled study of risperidone maintenance treatment in children and adolescents with disruptive behavior disorders. American Journal of Psychiatry 2006, 163:402-410.
83. Richdale A., Francis A., Gavidia-Payne S., Cotton S. Stress, behaviour and sleep problems in children with intellectual disability. Journal of Intellectual and Developmental Disability 2000, 25:147-161.
84. Richman N A double-blind drug trial of treatment in young children with waking problems. Journal of Child Psychology and Psychiatry 1985, 26:591-598.
85. Robinson A.M., Richdale A.L. Sleep problems in children with intellectual diability: Parental perception of sleep problems and views of treatment effectiveness. Child Care Health and Development 2004, 30:139-150.
86. Roehrs T., Roth T. Safety of insomnia pharmacotherapy. Sleep Medicine Clinics 2006, 1:399-407.
87. Rossi P.G., Posar A., Parmeggiani A. Niaprazine in the treatment of autistic disorder. Journal of Child Neurology 1999, 14:547-550.
88. Roth T., Seiden D., Sainati S., Wang-Weigand S., Zhang J., Zee P. Effects of Ramelteon on patient-reported sleep latency in older adults with chronic insomnia. Sleep Medicine 2005, 7:312-318.
89. Roth T., Stubbs C., Walsh J.K. Ramelteon (TAK-375), a selective MT1/MT2-receptor agonist, reduces latency to persistent sleep in a model of transient insomnia related to a novel sleep environment. Sleep 2005, 28:303-307.
90. Russo R.M., Vymutt J., Gurura J., Allen J.D. The effectiveness of diphenhydramine in pediatric sleep disorders. Journal of Clinical Pharmacology 1976, (May-June):284-288.
91. Saletu-Zyhlarz G.M., Abu-Bakr M.H., Anderer P., Gruber G., Mandl M., Strobl R., et al. Insomnia in depression: Differences in objective and subjective sleep and awakening quality to normal controls and acute effects of trazodone. Progress in Neuro-Psychopharmacology & Biological Psychiatry 2002, 26:249-260.
92. Saletu-Zyhlarz G.M., Abu-Bakr M.H., Anderer P., Semler B., Decker K., Parapatics S., et al. Insomnia related to dysthymia: Polysomnographic and psychometric comparison with normal controls and acute therapeutic trials with trazodone. Neuropsychobiology 2001, 44:139-149.
93. Sateia M.J., Kirby-Long P., Taylor J.L. Efficacy and clinical safety of ramelteon: An evidence-based review. Sleep Medicine 2008, 12:319-332.
94. Schnoes C.J, Kuhn B.R., Workman E.F., Ellis C.R. Pediatric prescribing practices for clonidine and other pharmacologic agents for children with sleep disturbance. Clinical Pediatrics 2006, 45:229-238.
95. Seibt J., Aton S.J., Jha S.K., Coleman T., Dumoulin M.C., Frank M.C. The non-benzodiazepine hypnotic zolpidem impairs sleep-dependent cortical plasticity. Sleep 2008, 31:1381-1391.
96. Selcuk A., Isik E., Cosar B. The effects if mirtazapine on sleep: A placebo-controlled, double-blind study in young healthy volunteers. Sleep 2002, 25:666-668.
97. Shakibaei F., Gholamrezaei A., Heidari S. Effect of trazodone on sleep bruxism in children and adolescents 6-18 years of age, a pilot study. Journal of Research in the Medical Sciences 2008, 13:29-33.
98. Simonoff E.A., Stores G. Controlled trial of trimeprazine tartrate for night waking. Archives of Disease in Childhood 1987, 62:253-257.
99. Smits M.G., Nagtegaal E.E., van der Heijden J., Coenen A.M.L., Kerkhof G.A. Melatonin for chronic sleep onset insomnia in children: A randomized placebo-controlled trial. Journal of Clinical Child Neurology 2001, 16:86-92.
100. Smits M.G., van Stel H.F., van der Heijden K.B., Meijer A.M., Coenen A.M., Kerkhof G.A. Melatonin improves health status and sleep in children with idiopathic chronic sleep-onset insomnia: A randomized placebo-controlled trial. Journal of the American Academy of Child and Adolescent Psychiatry 2003, 42:1286-1293.
101. Sprague R.L., Werry J.S. Methodology of psychopharmacological studies with the retarded. International review of research in mental retardation 1971, 147-219. Academic Press, New York. N.R. Ellis (Ed.).
102. Staner L., Kerkhofs M., Detroux D., Leyman S., Linkowski P., Mendlewicz J. Acute, subchronic and withdrawal sleep EEG changes during treatment with paroxetine and amitriptyline: A double-blind randomized trial in major depression. Sleep 1995, 18(6):470-477.
103. Stickhold R. Sleep-dependent memory consolidation. Nature 2005, 437:1272-1278.
104. Stickhold R., Hobson .A., Fosse R., Fosse M. Sleep, learning, and dreams: Off-line memory reprocessing. Science 2001, 294:1052-1057.
105. Stigler K.A., Posey D.J., McDougle C.J. Case report: Ramelteon for insomnia in two youths with autistic disorder. Journal of Child and Adolescent Psychopharmacology 2006, 16:631-636.
106. Stojanovski S.D., Rasu R.S., Balkrishan R., Nahata M.C. Trends in medication prescribing for pediatric sleep difficulties in US outpatient settings. Sleep 2007, 30:1013-1017.
107. Thirumalai S.S., Shubin R.A., Robinson R. Rapid eye movement sleep behavior disorder. Journal of Child Neurology 2002, 17:173-178.
108. Troost P.W., Lahaus B.E., Steenhuis M.P., Ketelaars C.E.J., Buitelaar J.K., Van Engeland H., et al. Long-term effects of risperidone in children with autism spectrum disorders: A placebo discontinuation study. Journal of the American Academy of Child and Adolescent Psychiatry 2005, 44:1137-1144.
109. U.S. Department of Health and Human Services: Agency for Healthcare Research and Quality (AHRQ). (2004). Melatonin for treatment of sleep disorders (Evidence Report/Technology Number 108). Retrieved September 5th, 2009 []. http://www.ahrq.gov/downloads/pub/evidence/pdf/melatonin/melatonin.pdf.
110. van der Heijden K.B., Smits M.G., van Someren E.J.W., Ridderinkhof R.R., Gunning W.B. Effect of Melatonin on sleep, behavior and cognition in ADHD and chronic sleep-onset insomnia. Journal of the American Academy of Child and Adolescent Psychiatry 2007, 46:233-241.
111. Wagner M.L, Walters A.S., Coleman R.G., Hening W.A., Grasing K., Chokraverty S. Randomized double-blind placebo-controlled study of clonidine in restless leg syndrome. Sleep 1996, 19:52-58.
112. Walker M.P., Stickhold R. Sleep, memory, plasticity. Annual Review of Psychology 2006, 57:139-166.
113. Walsh J.K., Fry J., Erwin C.W., Scharf M., Roth T., Vogel G.W. Efficacy and tolerability of 14-day administration of zaleplon 5mg and 10mg for the treatment of primary insomnia. Clinical Drug Investigations 1998, 16:347-354.
114. Walsh J.K., Vogel G.W., Scharf M., Erman M., Erwin C.W., Schweitzer P.K., et al. A five week, polysomnographic assessment of zaleplon 10mg for the treatment of primary insomnia. Sleep Medicine 2000, 1:41-49.
115. Wasdell B., Jan J.E., Bomben M.M., Freeman R.D., Rietveld W.J., Tai J., et al. A randomized, placebo-controlled trial of controlled release melatonin treatment of delayed sleep phase syndrome and impaired sleep maintenance in children with neurodevelopmental disabilities. Journal of Pineal Research 2007, 44:57-64.
116. Weiss M.D, Wasdell M.B., Bomben M.M., Rea K.J., Freeman R.D. Sleep hygiene and melatonin treatment for children and adolescents with ADHD and initial insomnia. Journal of the American Academy of Child and Adolescent Psychiatry 2005, 45:512-519.
117. Wiggs L., Stores G. Severe sleep disturbance and daytime challenging behavior in children with severe learning disabilities. Journal of Intellectual Disability Research 1996, 40:518-528.
118. Wilkinson L. Task force on statistical inference APA board of scientific affairs. Statistical methods in psychology journals: Guidelines and explanations. American Psychologist 1999, 54:594-604.
119. Zametkin A.J., Reeves J.C., Webster L., Werry J.S. Brief Communication: Promethazine treatment of children with attention deficit disorder with hyperactivity-ineffective and unpleasant. Journal of the American Academy of Child Psychiatry 1986, 25:854-856.
120. Zammit G., Erman M., Wang-Weigand S., Sainati S., Zhang J., Roth T. Evaluation of the efficacy and safety of Ramelteon in subjects with chronic insomnia. Journal of Clinical Sleep Medicine 2007, 3:495-504.
121. Zito J.M., Safer D.J., dosReis S., Gardner J.F., Boles M., Lynch F. Trends in the prescribing of psychotropic medications to preschoolers. Journal of the American Medical Association 2000, 283:1025-1030.